Myocardial Infarction
📧 Sign up to get email alerts when something new happens for Myocardial Infarction.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-07-17Clinical Trial Update: A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk [NA]
A completed clinical trial evaluated a smartphone-based application to manage cardiovascular disease risk after myocardial infarction in pat…
-
FDA approval · 2023-07-05FDA Approved: LOPRESSOR — Supplemental Application (Validus Pharmaceuticals LLC)
FDA approved a supplemental application for Lopressor (metoprolol tartrate) submitted by Validus Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI [Phase 3]
Phase 3 trial comparing ARNI versus ACE inhibitor to determine superiority in reducing heart failure events after acute myocardial infarctio…
-
FDA approval · 2023-06-08FDA Approved: CLOPIDOGREL — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for a generic clopidogrel product from Aurobindo Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2023-06-08Clinical Trial Update: Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial [Phase 1, Phase 2]
Clinical trial evaluating nivolumab versus placebo in patients with acute myocardial infarction (acute anterior ST-segment elevation); both …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2023-06-01EMA Authorised: Rapilysin (reteplase) — Actavis Group PTC ehf
Rapilysin (reteplase) has been authorised in the EU for myocardial infarction, with Actavis Group PTC ehf as the marketing authorisation hol…
-
FDA approval · 2023-05-25FDA Approved: EPTIFIBATIDE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for the generic drug Eptifibatide filed by Eugia US LLC (ANDA 206127).
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Southwest German Interventional Study in Acute Myocardial Infarction III [Phase 4]
Phase 4 interventional trial update for acute myocardial infarction conducted in Southwest German centers; study status completed.
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study [Phase 3]
A Phase 3 pilot study evaluating the effectiveness of a lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA) has…
-
FDA approval · 2023-04-21FDA Approved: TICAGRELOR — Original Application (Ascend Laboratories, LLC)
FDA approved Ticagrelor under an Original Application by Ascend Laboratories, LLC. The approval supports its use as an antiplatelet therapy …
-
CLINICAL_TRIALS trial_result · 2023-04-13Clinical Trial Update: BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction [NA]
A completed clinical trial update from Biotronik evaluating monitoring in patients after myocardial infarction with preserved left ventricul…
-
CLINICAL_TRIALS trial_result · 2023-04-11Clinical Trial Update: The Impact of Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling [Phase 4]
Phase 4 trial evaluating the impact of Compound Danshen Dropping Pills (CDDP) on post-myocardial infarction ventricular remodeling.
-
CLINICAL_TRIALS trial_result · 2023-04-05Clinical Trial Update: Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack [Phase 2]
Phase 2 trial assessing dosing and safety of the oral FXIa inhibitor BAY 2433334 after acute myocardial infarction has completed with result…
-
FDA approval · 2023-03-31FDA Approved: TNKASE — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for TNKASE (tenecteplase) from Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction [Phase 2]
Phase 2 trial investigating firibastat or ramipril after acute myocardial infarction to prevent left ventricular dysfunction has completed w…
-
CLINICAL_TRIALS trial_result · 2023-01-30Clinical Trial Update: SP16 Inflammatory Response Inhibition Trial [Phase 1, Phase 2]
Clinical trial update for SP16 inflammatory response inhibition shows completed Phase 1 and Phase 2 studies with results posted.
-
FDA approval · 2023-01-27FDA Approved: CAPTOPRIL — Original Application (AiPing Pharmaceutical, Inc.)
The FDA approved AiPing Pharmaceutical’s Original Application for CAPTOPRIL (captopril), a generic ACE inhibitor. The approval supports indi…
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles [Phase 4]
Phase 4 trial update evaluating 3D PET myocardial blood flow and Rb82 infusion profiles in normal healthy volunteers and individuals with co…
-
CLINICAL_TRIALS trial_result · 2023-01-13Clinical Trial Update: The OPTIMA-5 Trail [Phase 4]
Phase 4 trial update for OPTIMA-5 Trial completed, focusing on Acute Myocardial Infarction.
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Co-transplantation of Mesenchymal Stem Cell Derived Exosomes and Autologous Mitochondria for Patients Candidate for CABG Surgery [Phase 1, Phase 2]
Phase 1/2 trial evaluating co-transplantation of mesenchymal stem cell-derived exosomes and autologous mitochondria for patients undergoing …
-
CLINICAL_TRIALS trial_result · 2022-12-29Clinical Trial Update: Chronic Kidney Disease (CKD) Platelet Study [Phase 3]
Phase 3 clinical trial update for a CKD-related platelet study; study completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-12-12Clinical Trial Update: In-hospital Clinical Outcome of Deferred Stenting Versus Immediate Stenting in the Management of Acute STEMI Presenting With High Thrombus Burden. [Phase 2]
Phase 2 trial update comparing deferred stenting to immediate stenting in acute STEMI with high thrombus burden; outcome data not yet availa…
-
CLINICAL_TRIALS trial_result · 2022-12-07Clinical Trial Update: Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients [Phase 4]
Phase 4 trial comparing zotarolimus-, sirolimus-, and paclitaxel-eluting stents in acute myocardial infarction was terminated.
-
FDA approval · 2022-11-15FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Amphastar Pharmaceuticals, Inc.)
FDA approves Amphastar Pharmaceuticals' supplemental application for enoxaparin sodium.
-
CLINICAL_TRIALS trial_result · 2022-11-15Clinical Trial Update: Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention [Phase 4]
Phase 4 trial update on prolonged enoxaparin in primary percutaneous coronary intervention for myocardial infarction.